Farmacias Benavides - CEO, Guillermo Demis
CEO, Guillermo Demis
Source: Reform
  • Diagnos Inc. (ADK) signs a contract with Farmacias Benavides, a member of Walgreens Boots Alliance in Mexico
  • Diagnos’ AI retina service begin shortly via the Benamedic Wellness program
  • Benamedic is a catalog of medical services carried out by Farmacias Benavides
  • Diagnos uses non-invasive pre-screening technology for early retina diseases detection
  • Diagnos Inc. (ADK) is down 2.50 per cent trading at $0.19 per share as of 2:25 p.m. ET.

Diagnos (ADK) has signed a contract with Farmacias Benavides, a member of Walgreens Boots Alliance in Mexico.

Diagnos’ AI retina service begin in the next few weeks through the Benamedic Wellness program.

Benamedic is a catalogue of medical services carried out by Farmacias Benavides through its extensive network of doctors at the points-of-care attached to the pharmacy stores.

Guillermo Demis, CEO of Farmacias Benavides, commented,

“As we keep our evolution into a much more digital health and integrated ecosystem, we’re happy to announce the service contract with Diagnos in order to support the Benamedic Wellness program… Diagnos uses non-invasive pre-screening technology done through the eye for early detection of retina diseases in real- time caused by diabetes, pre-diabetes (obesity) and hypertension.”

Farmacias Benavides is the market leader in retail sales of health and wellness products in Mexico. With more than a century of experience, it has established itself in more than 197 cities in 24 states.

Farmacias Benavides owns a network of more than 1,100 pharmacies, 400 medical offices, and a high-tech distribution center. The chain is operated by more than 8,000 collaborators offering a catalog of more than 16,000 different products of commercial and own brands focused on helping the health and well-being of its customers.

Walgreens Boots Alliance is an integrated healthcare, pharmacy and retail company serving millions of people every day. It has approximately 13,000 locations across the U.S., Europe, and Latin America.

Diagnos Inc. (ADK) is down 2.50 per cent trading at $0.19 per share as of 2:25 p.m. ET.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.